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Agroindustrial residues, such as leaves of fruit plants, can be sources of bioactive molecules, 
thus adding value to co-products that are rarely explored in agroindustry. In this context, this study 
aimed to look into the phytochemical profiles in detail and to explore the antitumor potential of 
S. tuberosa and S. mombin leaves. We observed that, S. tuberosa leaf extract was cytotoxic in both 
tumor and healthy cells. S. mombin extracts selectively inhibited cell proliferation in the tumor 
cell line for prostate cancer (PC3) and did not significantly affect healthy cells. The metabolic 
profiles of the extracts were evaluated by gas chromatography coupled with mass spectrometry and 
twenty-three metabolites were identified. The correlation of metabolic profiles with cytotoxic tests 
indicated possible chemical markers that may be responsible for the inhibition of cell proliferation. 
This study revealed that the unexplored co-products in agroindustry may have great therapeutic 
potential, and therefore should be screened for biologically active compounds.
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Introduction
Spondias mombin is present in tropical zone of 
Africa, South America, and Asia.1 In Brazil, it is widely 
cultivated, mainly in the North and Northeast regions.2 
Additionally, S. mombin is also found in Caribbean3 
and French Polynesian islands.4 On the other hand, 
Spondias tuberosa is an endemic fruit tree species native 
to the Brazilian semiarid region.5 Commercial production 
of umbu is non-existent, and demand for the fruit stems 
from domestic extractivism.6
Spondias tuberosa Arr. Cam. and Spondias mombin L. 
are representative species of tropical America, and are 
traditionally known in Brazil as umbu and yellow mombin, 
respectively.2,5 These exotic species belong to the Spondias 
genus of the family Anacardiaceae;7 their fruits have 
recognized nutritional,5,8 medicinal,7 and commercial 
value.9-11
Spondias has been widely used as a popular treatment 
for several diseases. Specifically, S. mombin has been 
used as a diuretic, and is also used to treat various nervous 
disorders.1 Further, it presents potential anti-fertility and 
abortifacient activities.12-14 S. tuberosa has been used in 
digestive disorders, diarrhea, and menstrual abnormalities.15 
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In an earlier study,15 S. tuberosa ethanol extracts in rats 
showed antidiabetic effects. In addition, studies revealed 
that it also displays anti-inflammatory, antioxidant,16 and 
anticholinesterases activities.17 Both Spondias presents 
antibacterial, antimicrobial, and antiviral properties.18 
S. tuberosa seed extracts in methanol and chloroform 
half maximum lethal concentration ((LC50): 168.3 and 
152.26 μg mL−1, respectively)16 showed moderate cytotoxic 
activity in brine shrimps. 
The low cytotoxicity of Spondias demonstrated by 
various in vivo experimental models19 suggests that this 
species may be developed into a useful product. Currently, 
the literature lacks further information on the chemical 
profiles associated the cytotoxic activities of Spondias leaves. 
Thus, the purpose of this study was to examine 
unknown biological properties (anticancer) of S. mombin 
and S. tuberosa leaves, as well as to determine the 
metabolomic profiles of non-polar extracts based on 
gas chromatography-mass spectrometry (GC-MS) data. 
Also, we intend to correlate the chemical compounds 
identified with the cytotoxicity test results to determine 
the potential anticancer biomarkers. The results achieved 
in this study may provide new insight into the discovery 
and development of new drugs from agricultural inputs.
Experimental
Samples, reagents, and chemicals
Yellow mombin (S. mombin) and umbu leaves 
(S. tuberosa) were collected in Petrolina-PE, Brazil. 
Posteriorly, were dried (40 ºC for 3 days), grounded and 
stored for further extraction. This project is authorized by 
the Genetic Heritage Management Council. Accession to 
genetic patrimony No. AF91C72.
The N-trimethylsilyl-N-methyl trifluoroacetamide 
(MSTFA), pyridine, and the homologous series of n-alkane 
C8-C30 were purchased from Sigma-Aldrich (St Louis, MO, 
USA). Dimethyl sulfoxide (DMSO) and 3-(4,5-dimethyl-
2-thiazol)-2,5-diphenyl-2H-tetrazolium bromide (MTT) 
were purchased from Sigma-Aldrich (Darmstadt, 
Germany). Water was purified using a Milli-Q integral 
water purification system (Millipore, Bedford, MA, USA). 
The solvents used for extraction were analytical grade 
(ethanol (96%) and hexane (95%)) and were purchased 
from Tedia (Rio de Janeiro, RJ, Brazil). 
Extraction and derivatization
The samples (500 mg) were extracted with 4 mL 
hexane, vortexed for 1 min and ultrasound bath for 20 min, 
centrifuged at 3000 rpm for 10 min, and suspended plant 
materials were decanted. Posteriorly, a 3 mL of the extract 
was concentrated under vacuum on a rotary evaporator. The 
extraction was performed in quadruplicates for S. mombin 
and S. tuberosa.20-22
The derivatization of the extract was designed by 
the method described in the literature, where 10 mg of 
dry extract were solubilized in pyridine (200 μL). After, 
was added MSTFA (200 μL), and water bath at 37 °C for 
30 min.23 The extracts were then filtered and stored for 24 h 
at 4 °C prior to chromatographic analysis. 
Chromatographic analysis of extracts 
The chromatographic analyzes performed on the GC-MS 
7890B/MSD-5977A (Agilent, California, USA) equipment 
were programmed in the same conditions as reported in a 
paper described in the literature.22 Additionally, the extracts 
containing the derivatized compounds were designated by 
standard data (National Standards and Technology - NIST). 
Besides, the linear retention indices (LRI) of a series of 
n-C8-C30 alkanes was used to distinguish the metabolites 
tentatively identified.24
Biological tests 
The leaf extracts of S. mombin and S. tuberosa were 
performed by in vitro tests (MTT assays) against different 
cancer cell lines: prostate (PC3), human colon carcinoma 
(HCT-116), astrocytoma (SNB19), leukemia (HL60), breast 
(MCF-7), cervix (HeLa), and murine fibroblast (L929). The 
selectivity index of the metabolites for proliferation of a 
non-tumor cell line (L929) was used as control. Tumor cell 
lines were cultured according to the methodology described 
in the literature.22 
Evaluation of cytotoxicity
The viability of the healthy and diseased cell line was 
assessed by the MTT assay using doxorubicin as a positive 
control.25 All experimental conditions, obtaining and 
analyzing the half maximal inhibitory concentration (IC50) 
and growth inhibition (GI, %) were carried out as set out in 
literature.22 Also, to evaluate the cell-killing potential of the 
extracts, the following intensity scale reported in literature 
was used: GI, %, high (75-100%) and moderate (51-74%).26,27
Chemometric analysis
The extractions were obtained in four biological 
replicates of S. mombin and S. tuberosa, totaling eight 
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chromatograms. Thus, the chromatograms were imported 
and analyzed in the Origin™ program28 for construction of 
matrix data. Subsequently, the matrix data obtained by this 
method were used for principal component analysis (PCA), 
and partial least squares (PLS) analyzes on Unscrambler 
X™ program 10.4 software.29
Decomposition of the matrix by singular value 
decomposition (SVD) algorithm, correction of the baseline, 
a step of standardization of the data (normalization) and, 
finally, scaling of the centered composition in the mean 
was performed.30 Through the PCA, important information 
about the similarities and differences between the sample 
sets was obtained, at 95% confidence level.
In order to correlate the idication of possible marker 
compounds based on biological tests with the species of 
leaves and to improve the relationship between samples and 
composition, regression modeling by PLS was developed 
using each cytotoxic activity as a categorical variable. 
The nonlinear iterative partial least squares (NIPALS) 
algorithm was used for model construction. The number 
of latent variables (LV) were established in accordance 
to the following statistical parameters: root mean square 
error of calibration (RMSEC), root mean square error of 
cross validation (RMSECV), and the respective calibration 
coefficient (R2).31,32
Results and Discussion
Cytotoxicity
Through single-concentration initial screening tests 
(100 μg mL−1), we showed that hexane leaf extracts from 
S. tuberosa resulted in more than 70% growth inhibition 
(90.48 to 99.23%) in all cell lines tested. S. mombin 
extracts were cytotoxic against prostate cell lines only, at 
an inhibition rate of 75.28% and showed low cytotoxicity 
to the non-tumoral cell line (L929). Table 1 describes 
the percentages of inhibition of cell proliferation of leaf 
extracts from S. mombin and S. tuberosa against the tumor 
cells lines HCT-116 (colon carcinoma), PC3 (prostate), 
HL60 (leukemia), MCF-7 (breast), SNB19 (astrocytoma), 
and HeLa (cervix). Data are shown as mean cell growth 
inhibition against the cell lines, illustrated at Figure 1.
It is known that the percentage of inhibition of cell 
growth is high when it is between 75% and 100%, and 
moderate when the inhibition is between 51% and 74%.22 In 
Figure 1. Inhibitory effect of hexanic extracts from leaves of S. mombin and S. tuberosa.
Table 1. Inhibition percentage of cell growth of hexanic extracts from S. mombin and S. tuberosa leaves, determined by MTT assay after 72 h of incubation, 
at a concentration of 100 μg mL−1
Species
Inhibition of cell growtha / (GI% ± SD)
HCT-116 
(human colon)
HL60 
(leukemia)
PC3 
(prostate)
SNB19 
(astrocytoma)
MCF-7 
(breast)
HeLa 
(cervix)
L929 
(fibroblast)
S. mombin 47.44 ± 1.13 40.09 ± 0.23 75.28 ± 3.73 20.62 ± 4.02 26.60 ± 6.11 40.68 ± 2.76 44.63 ± 2.31
S. tuberosa 92.53 ± 0.52 90.48 ± 0.29 97.90 ± 0.73 98.41 ± 0.42 99.23 ± 0.60 93.78 ± 1.53 90.59 ± 2.19
Doxb, IC50c / (μg mL−1) 0.11 (0.08-0.14)
0.01 
(0.006-0.01)
0.44 
(0.34-0.54)
1.20 
(1.03-1.39)
0.08 
(0.07-0.11) –
0.99 
(0.91-1.08)
aExpressed as average of inhibition percentage of cell growth (GI%, growth inhibition) from two independent experiments in triplicate ± the standard 
deviation; bdoxorubicin was the positive control; cdrug concentration that caused 50% inhibition of cell growth, with a 95% confidence interval.
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this regard, S. tuberosa extracts presented higher activities 
against all tumor cell lines (HCT-116, HL60, PC3, SNB19, 
MCF-7, and HeLa) as compared to S. mombin. Conversely, 
S. tuberosa extracts also exhibited low selectivity between 
tumor and non-tumor cells (high L929 percentage). 
Studies have been using the L929 cell line to verify 
compound selectivity, da Cruz et al.33 and Vieira et al.34 
used the cell line to evaluate the selectivity of the 
quinones. Assanga et al.35 verified the growth curves of 
tumor and non-tumor cell lines treated with extracts of 
Phoradendron californicum, evaluating the selectivity 
index of the extracts in L929 lineage and verified that the 
extracts were selective to the tumoral ones. Wang et al.,36 
Oliveira et al.37 and Moura et al.38 showed that their 
compounds were selectively toxic to tumor lineages and 
had lower non-tumor linear toxicity.
Compounds that exhibit about two-fold increased 
selectivity in tumor cells than in non-tumor cells are 
promising compounds for mechanism of action studies.39 
The L929 cell line was studied as a normal murine cell 
line control by Salido et al.,40 verifying that the extracts 
of L. tridentata were more selective for the tumor cells, 
indicating possible decreases in side effects when compared 
to existing drugs in the clinic. 
Studies evaluated the cytotoxic activity of stem bark 
extracts from two species of the family Annonaceae; 
active extracts that resulted in more than 75% cell growth 
inhibition in any cell line was characterized.26 Another study 
examined compounds with very potent activities, which 
resulted in cell growth inhibition ranging from 75-100%.41 
In this work, S. tuberosa showed high inhibition potential 
(93.78%) against the HeLa cell line. This data supported 
study results reported in the literature, which showed 
similar activity with extracts from Salvia sahendica; these 
extracts resulted in 100% inhibition at a concentration of 
100 μg mL−1 for the same lineage and was categorized as 
a highly cytotoxic species.42 
Hexane extracts of S. tuberosa bark in human 
epidermoid cancer cells (HEp-2 cells) did not cause 
cytotoxicity at any concentration; conversely, an increase 
in cell number was observed at 250 μg mL−1.43 In this 
study, Spondias mombin extracts inhibited cell growth by 
92.53% in HCT-116 cells, 98.41% in SNB19 cells, 99.23% 
in MCF-7 cells, and 90.48% in HL60 cells.
Spondias mombin leaf extracts inhibited cell growth 
by 75.28% in the prostate cell line. Studies revealed that 
the extract of this species demonstrated an IC50 value 
of < 5 μg mL−1 against the cell line MRC-5 (lung).44 
Aqueous S. mombin extracts exhibited the potential to 
induce genetic damage in both somatic and germ cell 
lines. In addition, they counteracted the effects of known 
mutagens or carcinogens,45 which may be responsible 
for the difference in their bioactivities. Therefore, 
Spondias mombin can be a good source of natural 
pesticides and antitumor agents.46
Among the compounds identified in S. tuberosa, 
some studies reported the presence of α-cadinol in 
Pallenis spinose extracts, which inhibited proliferation of 
leukemic and solid tumor cells (MCF-7, HepG2, HT-1080, 
and Caco-2) with an IC50 in the ranges of 0.25-0.66 μg mL−1 
and 0.50-2.35 μg mL−1, respectively.47 Another compound 
identified was stearic acid, which is associated with reduced 
cardiovascular and cancer risks.48
Palmitic acid, present in both species, has induced 
senescence in hepatocellular cells and also impairs the 
expression of the SMARCD1 gene, which appears to be 
responsible for the accumulation of lipids associated with 
aging in the hepatic cell.49 Squalene and α-amyrin, together 
with other compounds present in Wrightia pubescens 
extracts, were effective against HT-29 (cell line colon) with 
an IC50 of 1.70 μg mL−1.50 The compound β-amyrin showed 
cytotoxic effects against HCT-116 cells, and was the most 
active compound in Vicia monantha subsp. monantha seed 
extracts (IC50 = 22.61 μg mL−1).51
Our study results demonstrated that S. tuberosa 
hexane extracts show greater cytotoxicity as compared 
to S. mombin extracts in all tested cell lines. However, 
S. tuberosa leaf extracts exhibited low selectivity between 
tumor and non-tumor cells. In contrast, S. mombin leaf 
extracts were efficient against PC3 tumor cells, and also 
showed high selectivity between tumor and non-tumor 
cells. Our results also provide evidence that plants of 
this genus are rich sources of active metabolites showing 
cytotoxic activities. As these extracts show potent 
inhibitory effects on cell growth, future studies should 
focus on studying the possible molecular mechanisms 
of cytotoxicity.
Metabolic profile of S. mombin and S. tuberosa
An overall of 23 metabolites from S. mombin and 
S. tuberosa leaf extracts were characterized. Figure 2 
illustrates the compounds identified in chromatograms from 
each extract; Table 2 describes the respective retention time, 
retention index, percentage of match, and representative 
ions (m/z) of the isolated compounds; these were found to 
be mainly organic acids (such as esters, carboxylic acids 
and fatty acid) and lipophilic vitamins. As expected, the 
profiles of S. mombin and S. tuberosa leaf extracts exhibited 
many similarities, since they belong to the same genus. 
However, differences in the levels of some metabolites 
were observed (Figure 2). 
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Chemometric evaluation
Due to the complexity and high dimensionality of the 
dataset obtained by GC-MS (total of 23 compounds × 
8 chromatograms = 184 variables), exploratory chemometric 
analysis by principal component analysis (PCA) was 
developed to evaluate the variability in the organic 
composition of S. mombin and S. tuberosa leaves. Figure 3 
illustrates the results; bidimensional scores (PC1 × PC2) are 
shown on the top left (Figure 3a), influence plots of extracts 
Table 2. Compounds identified in hexane extracts from S. mombin and S. tuberosa leaves
Compound name tRa / min RIexpb RIlitc Matchd R. matchd
Representative 
fragment ions (m/z) S. mombin S. tuberosa
α-Cadinol 15.89 1656 1652 875 926 43, 95 (BPe), 121, 
161, 204, 222 (M+•f)
+
Dodecanoic acidg 23.26 1881 1881 817 846 73, 75, 95, 129, 
257 (BP)
+
Myristic acidg 29.46 2080 2080 947 948 73, 75, 117, 129, 
285 (BP), 342 (M+•)
+ +
Malic acidg 30.24 2107 2095 759 902 73 (BP), 115, 147, 
287, 419
+
Pentadecanoic acidg 32.39 2181 2181 876 893 73, 75, 117, 129, 
299 (BP), 356 (M+•)
+
cis-9-Hexadecenoic acidg 34.97 2272 2269 812 813 73, 75, 129, 
311 (BP), 353
+ +
Palmitic acidg 35.36 2287 2281 948 948 73, 75, 117, 129, 
313 (BP), 370 (M+•)
+ +
Margaric acidg 37.98 2384 2388 801 901 73, 75, 117, 129, 
327 (BP), 384 (M+•)
+
Linoleic acidg 39.85 2455 2462 945 945 73, 75, 129, 
337 (BP), 379
+ +
9,12,15-Octadecatrienoic acidg 40.07 2467 2470 953 956 73, 75, 95, 129, 
335 (BP), 392 (M+•)
+ +
stearic acidg 40.64 2486 2483 810 910 73, 75, 117, 129, 
341 (BP), 398 (M+•)
+
Nonadecanoic acidg 43.14 2585 2584 768 906 73, 75, 117, 129, 
355 (BP), 412 (M+•)
+
Citric acidg 43.96 2618 2590 820 837 73 (BP), 147, 357, 
431, 459, 591
+
Squalene 48.94 2830 2836 963 966 69 (BP), 81, 95, 
121, 137
+ +
Behenic acidg 50.27 2889 2910 926 936 73, 75, 117, 129, 
397 (BP)
+
Tricosanoic acidg 52.48 2990 2985 856 890 73, 75, 117, 129, 
411 (BP)
+ +
Tetracosanoic acidg 54.65 > 3000 3088 909 927 73, 75, 117, 129, 
425 (BP), 482 (M+•)
+ +
α-Tocopherolquinone 55.70 > 3000 – 709 774 150, 165, 178, 221 
(BP), 430, 446 (M+•)
+ +
δ-Tocopherolg 55.92 > 3000 3153 714 715 73, 195, 251, 291, 
516 (BP, M+•)
+
γ-Tocopherolg 58.28 > 3000 3269 615 631 73, 209, 265, 305, 
530 (BP, M+•)
+
β-Amyrin 59.30 > 3000 3314 852 904 95, 203, 218 (BP), 
426 (M+•)
+
α-Amyrin 60.31 > 3000 3355 863 889 95, 135, 189, 203, 
218 (BP), 426 (M+•)
+ +
α-Tocopherolg 62.79 > 3000 3419 736 774 73, 207, 221, 
544 (BP, M+•)
+ +
 
aRetention time; bexperimental retention index; cretention index from literature; dreverse match value high: all masses in the library spectrum are present in 
the sample spectrum and match value low: the sample spectrum has more mass signals than the library spectrum; ebase peak; fmolecular ion; gcompounds 
as trimethylsilyl (TMS) derivatives.
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based on Hotelling’s T2 versus F-residuals modeling of PC1 
are shown on the top right (Figure 3b), and the relevant 
loadings for samples are shown on the bottom (Figure 3c).
According to the scores plot (Figure 3a), PC1 retained 
almost all model variability of extract samples, at 98.5% 
total variance. In addition, compositions of S. tuberosa leaf 
extracts were more homogeneous as compared with those of 
S. mombin (Figure 3b), which supports its high influence on the 
model. At large, the respective loadings (PC1) represented the 
topmost amounts of squalene, behenic acid, tricosanoic acid, 
tetracosanoic acid, and δ-tocopherol S. mombin extracts. In 
contrast, S. tuberosa extracts presented higher levels of myristic 
acid, cis-9-hexadecenoic acid, palmitic acid, α-tocopherol, 
stearic acid, linoleic acid and 9,12,15-octadecatrienoic acid.
Figure 2. Chromatograms (same scale) obtained by GC-MS of the hexane extracts from Spondias leaves: green denotes S. tuberosa and oranges denotes 
S. mombin. 
Figure 3. Chemometrics analysis: (a) bidimensional scores coordinate system (PC1 × PC2) from S. mombin and S. tuberosa leaf extracts; (b) influence 
plot from Hotelling’s T2 × F-residuals; (c) line forms of relevant loadings.
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Unsupervised chemometric evaluation of PCA was 
carried out to examine the phytochemical profiles of 
S. mombin and S. tuberosa; results indicated high variability 
between species. Therefore, due to the elevate amount of 
information, a heat map analysis was developed and shown 
in Figure 4 as a 3D dendrogram (samples × retention 
times × signals intensity). The analysis highlighted the 
difference between S. mombin and S. tuberosa samples, 
which is attributed to higher levels of various compounds 
at 29.46 min (myristic acid), 34.97 min (cis-9-hexadecenoic 
acid), 35.36 min (palmitic acid), 39.85 min (linoleic acid), 
40.07 min (9,12,15-octadecatrienoic acid), 40.64 min 
(stearic acid), and 48.94 min (squalene) in S. tuberosa as 
compared with those in S. mombin samples. On the other 
hand, several compounds were elevated at 50.27 min 
(behenic acid), 52.48 min (tricosanoic acid), 54.65 min 
(tetracosanoic acid), and 55.92 min (δ-tocopherol) in 
S. mombin samples. 
Based on results from the PCA and cytotoxic activities 
described in Table 1, a regression model by PLS was 
developed using each cytotoxic activity as a categorical 
variable to define the association between samples, cytotoxic 
activities, and marker compounds. The statistical parameters 
used to achieve model qualities are described in Table 3.
The high explained variance in the PC1 axis, the 
calibration coefficient (R2), and the similarity criteria for 
both calibration and cross validation presented elevate 
classification quality in all models. Furthermore, proximity 
between the values prevented clear indication of the most 
appropriate regression models. However, the prostate 
activity (PC3) model showed the lowest calibration and 
validation errors, which indicated that this model may 
appropriately describe the relationship between extract 
composition and cytotoxic activity. 
High cytotoxic activities were showcased by S. tuberosa 
extracts against both tumor and non-tumor cell lines; 
S. mombin extracts were only cytotoxic toward prostate 
tumor cells, which suggested that leaves extract of 
S. mombin may be more relevant for our study purposes.
The metabolites myristic acid, cis-9-hexadecenoic acid, 
palmitic acid, linoleic acid, 9,12,15-octadecatrienoic acid, 
and stearic compounds may be associated with elevated 
activity against the tumor cells lines human colon, prostate, 
astrocytoma, breast, cervix, and the non-tumor cells line 
L929 (Figure 3). A previous study showed that palmitic 
acid and 9,12-octadecadienoate in hexane extracts from 
pineapple leaves are markers for cytotoxic activity against 
the human colon, prostate, astrocytoma, breast, and 
cervix cell lines. In addition, margaric acid, stigmasterol, 
cis-11-eicosenoic acid, and δ-tocopherol were also highly 
cytotoxic against the leukemia.22 
On the other hand, S. mombin leaf extracts exerted 
inhibitory effects on PC3 tumor cell proliferation and 
Table 3. Multivariate regression modeling using PLS for each tumor line tested
Model LV1a / % R2 calb RMSECc R2 vald RMSECVe RMSEC / RMSECVf
Human colon 99.99 0.999 0.234 0.999 0.347 0.67
Leukemia 99.99 0.999 0.261 0.999 0.388 0.67
Prostate 99.99 0.999 0.117 0.999 0.174 0.67
Astrocytoma 99.99 0.999 0.403 0.999 0.598 0.67
Breast 99.99 0.999 0.376 0.999 0.559 0.67
Cervix 99.99 0.999 0.275 0.999 0.408 0.67
L929 99.99 0.999 0.238 0.999 0.354 0.67
aTotal variance percent in X matrix refer to one latent variable (LV); bcalibration coefficient between the real value and the value predicted during the 
calibration; croot mean square error of calibration; dcalibration coefficient between the real value and the value predicted during the validation; eroot mean 
square error of cross validation; fsimilarity criterion.
Figure 4. Heat map showing the variability in the amounts of metabolites 
between S. mombin and S. tuberosa.
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demonstrated selectivity between tumor and non-tumor 
cells. Chemical markers that may be associated with 
cytotoxic activity against prostate tumor cells (PC3) were 
suggested to be squalene, tricosanoic acid, δ-tocopherol, 
and mainly the acids as well as behenic and tetracosanoic 
acids (Figure 3).
Behenic (C24:0) and tetracosanoic (C24:0) acids are 
important fatty acids. In general, lipids are able to modulate 
the viability of tumor cells.52-54 However, there is no direct 
evidence that suggests behenic and tetracosanoic acids are 
potential anti-cancer prostate agents.
Isoprenoid squalene was suggested to complement 
anticancer therapies.55 It is considered to be a potent chemo-
preventative and chemotherapeutic agent, and is able to 
inhibit tumor growth in ovarian, lung, skin, lung, breast, 
and colon cancers.56
Squalene is a lipid predecessor of (3β)-cholest-5-en-
3-ol production, which allows the bio-conjugates formed 
naturally to be able to self-modulate as nanoparticles 
to become better their biological activity.57 It has 
been reported that this lipid acts as a drug carrier by 
chemically linking with drugs to improve certain 
physicochemical properties. For example, administration 
of squalene-doxorubicin nanohybrids resulted in higher 
reduction of pancreatic tumors when compared with free 
doxorubicin. (95% versus 29%).58 Therefore, squalene-
based nanoparticles have been considered to be promising 
candidates for anti-cancer drugs.59-61 In the nutritional 
context, virgin olive oil is an important source of squalene.62 
Consumption of olive oil has been correlated with lower 
risk of tumor development in various cancer types.56,63,64
We found three vitamin E isoforms, α, γ and δ-tocopherol 
in S. tuberosa and S. mombin. Specifically, α-tocopherol 
was found in S. tuberosa hexanic extracts, while the other 
two isoforms were found only in S. mombin extracts. 
Recently, preclinical investigations into vitamin E 
isoforms revealed that aside from the non-alpha-tocopherol 
form, all others show promising anticancer effects.65 
Tocopherols, particularly the γ and δ homologs, have been 
shown to prevent the development of various kind of tumor, 
including prostate.65-67 
Studies that examined the synergistic effects of vitamin E 
isoforms against human androgen-dependent prostate 
cancer cells (LNCaP) indicated that the combination of 
δ-tocopherol and γ-tocotrienol significantly inhibits 
prostate cancer cell growth.68 
In contrast, a racemic tocopherol study in two prostate 
cancer cell lines (LNCaP and PC3) indicated that neither 
R,R,R-α-tocopherol nor R,R,R-γ-tocopherol exhibits 
inhibitory effects on cell development and apoptotic cell 
death.69 
Thereby, experimental evidence and literature data 
strongly supports the possibility of chemical markers of 
S. tuberosa and S. mombin being potential agents against 
tumor cells. In view of various reports regarding the 
potential of vitamin E isoforms, our experimental results 
suggested vitamin E isoforms act through synergistic 
effects.
Based on data presented to date, metabolites may exert 
potential cytotoxic activities in prostate cancer cells (PC3) 
and act as biomarkers. Among these, we propose that 
vitamin E isoforms (δ-tocopherol) and squalene are the 
major contributors for our experimental results.
Conclusions
In the chromatographic analyzes by GC-MS, 
twenty-three different metabolites were detected in 
hexane extracts from S. mombin and S. tuberosa. Using 
chemometric tools, we established chemical markers that 
distinguished between S. mombin (squalene, tricosanoic 
acid, δ-tocopherol, behenic acid and tetracosanoic acid) 
and S. tuberosa (myristic acid, cis-9-hexadecenoic acid, 
palmitic acid, 9,12,15-octadecatrienoic acid, linoleic acid, 
and stearic acid) leaf extracts, which may be associated with 
the observed differences in cytotoxic activity.
In addition, we verify that hexane extracts from 
S. tuberosa exhibited higher activities against all tumor cell 
lines as compared with those from S. mombin. Within the 
ambit, S. tuberosa showed potent cytotoxic activity against 
six tumor lines and demonstrated 90.48-99.23% inhibition 
against cell growth. However, hexane extract from 
S. tuberosa leaves showed low selectivity between tumor 
and non-tumor lines, and therefore are not ideal candidates 
for therapeutics. On the other hand, hexanic extracts 
from S. mombin exhibited lower proliferative inhibition 
(20.62-75.28%). Nevertheless, cell growth of prostate 
cell lines was inhibited by 75.28%. More importantly, 
S. mombin demonstrated high selectivity between tumor 
and non-tumor cells and is therefore considered a promising 
phytotherapeutic candidate against cancer. 
The results of this work demonstrate that hexane 
extracts of S. tuberosa present greater cytotoxic activity than 
S. mombin in all tested cell lines. Since existing literature 
lacks data on cytotoxicity of these two species, our work 
provides valuable information on the medicinal properties 
of these species. Our data suggest that S. tuberosa and 
S. mombin leaves are potentially important supplements 
because of their nutritional content and due to their ability 
to reduce the risk of cancer. In view of this, the above data 
suggest that these plant extracts may possibly be potential 
therapeutic agents.
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